What conditions is Aranesp (darbepoetin alfa) approved to treat?
Aranesp (darbepoetin alfa) is used to treat anemia in several settings. The common approved indications include anemia related to chronic kidney disease, and anemia related to certain cancer treatments (to reduce the need for red blood cell transfusions).
What anemia in kidney disease does Aranesp treat?
Aranesp is indicated for anemia in people with chronic kidney disease, including patients on dialysis and patients not on dialysis. It helps raise hemoglobin levels to reduce transfusion needs.
What anemia in cancer patients does Aranesp treat?
Aranesp is also used for anemia in patients with non-myeloid malignancies who receive chemotherapy. The goal is to reduce the need for red blood cell transfusions.
Who should not take Aranesp for anemia from cancer?
In general, erythropoiesis-stimulating agents like Aranesp are not intended for anemia in people whose cancer is not being treated with chemotherapy, and they are not used to target normal hemoglobin levels. Safety concerns (including risks tied to higher hemoglobin targets) drive these restrictions.
How do doctors decide which Aranesp indication applies?
Clinicians choose the indication based on the underlying cause of anemia:
- Chronic kidney disease (dialysis vs. non-dialysis) for renal anemia.
- Receiving chemotherapy for non-myeloid cancer-related anemia.
The dosing and treatment targets also depend on response and safety monitoring.
Is Aranesp used to treat anemia for reasons other than the above?
Aranesp’s use is tied to its approved anemia indications, which are designed around specific causes (chronic kidney disease or chemotherapy-associated anemia in non-myeloid malignancies). Off-label use can vary, but it depends on local practice and regulatory labeling.
Sources
No source links were provided in the prompt. If you share the Aranesp label text or a link (FDA label, EMA label, or DrugPatentWatch.com page), I can extract the exact, label-accurate indications and wording.